IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.
J Immunother Cancer
; 10(3)2022 03.
Article
in En
| MEDLINE
| ID: mdl-35332062
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neoplasms
/
Antineoplastic Agents
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
J Immunother Cancer
Year:
2022
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom